Our Passion
for Innovation

Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT_1A agonist activity that is under investigation for the treatment of schizophrenia, generalized anxiety disorder, the adjunctive treatment of major depressive disorder and other CNS conditions. Ulotaront is being jointly developed and commercialized in partnership with Otsuka Pharmaceuticals Co. Ltd. Sunovion discovered ulotaront in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube® platform and associated artificial intelligence algorithms. Ulotaront is being studied in a global Phase 3 development program for schizophrenia (DIAMOND) with additional indications under consideration. The U.S. FDA granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia in May 2019. The full results of a four-week pivotal study (SEP361-201) evaluating the safety and efficacy of ulotaront in patients with schizophrenia were published in the New England Journal of Medicine (NEJM) in April 2020.

Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1_1A agonist activity that is under investigation for the treatment of schizophrenia, the adjunctive treatment of major depressive disorder and other CNS conditions. Ulotaront is being jointly developed and commercialized in partnership with Otsuka Pharmaceuticals Co. Ltd.

Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1_1A agonist activity that is under investigation for the treatment of schizophrenia, generalized anxiety disorder the adjunctive treatment of major depressive disorder and other CNS conditions. Ulotaront is being jointly developed and commercialized in partnership with Otsuka Pharmaceuticals Co. Ltd.

SEP-4199 is is a non-racemic ratio of amisulpride in clinical development for the treatment of bipolar depression. The pharmacological effect of SEP-4199 is distinct from racemic amisulpride, which is approved in several countries outside the U.S. for the treatment for schizophrenia and other psychiatric conditions. Sunovion improved the antidepressant activity in amisulpride, which is believed to be driven by 5-HT7 receptor (5-HT7R) antagonism, and adjusted the dopamine D2/D3-mediated antipsychotic activity by discovering that each enantiomer favors a different receptor. The targeted levels of 5-HT7R antagonist and D2R/D3R blockade were independently studied for antidepressant effects in early human studies to discover that an 85:15 ratio of aramisulpride to esamisulpride provides antidepressant benefit and reduces D2 receptor-related extrapyramidal side effects, while still retaining D2 receptor binding-related benefit in bipolar disorder.

Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT_1A agonist activity that is under investigation for the treatment of schizophrenia, generalized anxiety disorder and other CNS conditions. Ulotaront is being jointly developed and commercialized in partnership with Otsuka Pharmaceuticals Co. Ltd. Sunovion discovered ulotaront in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube® platform and associated artificial intelligence algorithms.